Biocartis to present six abstracts at AMP 2024 annual meeting

Biocartis will present six Idylla™ abstracts at this year's Association for Molecular Pathology (AMP) Annual Meeting & Expo, Vancouver, Canada from November 19–23, showcasing the strong collaborations Biocartis has built with leading research and academic partners.

1. Performance Assessment and Clinical Validation of the Idylla™ IDH1-2 Mutation Assay Kit in Rapid Detection of IDH Mutations in Acute

By using 36 samples from 18 unique AML cases, the authors were able to demonstrate perfect concordance (100%) of the Idylla™ IDH1-2 Mutation Assay Kit with NGS. Directly using bone marrow aspirate in the cartridge significantly reduced turnaround time, making this technique an ideal solution for developing assays for AML diagnosis, prognosis, and treatment evaluation¹.

2. The Idylla™ Platform Enables Rapid and Accurate EGFR Mutation Assessment in NSCLC with Minimal Sample Input

This prospective study demonstrated how the Idylla™ EGFR Mutation Assay offered rapid and accurate detection of EGFR mutations in non-small cell lung cancer (NSCLC), with 95% concordance with NGS. The Assay successfully identified mutations in cases where NGS could not be performed (10% of the cohort) and reduced turnaround time from 12.1 to 1.7 days. With minimal sample requirements and hands-on time, Idylla™ provided a faster option for obtaining EGFR mutation status in NSCLC².

3. Re-verification and Report Ruling Revision of NTRK Fusion Results of Idylla™ GeneFusion Assay after Manufacturer Algorithm Update

This re-verification study of the Idylla™ GeneFusion Assay demonstrated improved sensitivity for detecting NTRK2 fusions, due to a software update. Although sensitivity for NTRK3 decreased slightly, updates to the laboratory’s standard operating procedure have enhanced accuracy by requiring confirmation testing for certain equivocal results. The study showed no changes to the detection of ALK, ROS1, RET, and MET fusions, maintaining 100% sensitivity and specificity³.

4. Rapid Determination of IDH1 and IDH2 Mutation Status in AML and Glioma Using Microfluidic Detection System

This study showed 97% accuracy, 100% sensitivity and 95% specificity for detecting IDH1 and IDH2 mutations in glioma and AML samples with the Idylla™ IDH1-2 Mutation Assay Kit. The Assay delivered rapid results within 95 minutes, with only one discordant case under investigation, potentially due to a higher sensitivity than the reference test. The Idylla™ System was praised for its ease of use and reliability, making it a valuable tool for determining IDH mutation status in various malignancies⁴.

5. The Idylla™ POLE Mutation Assay, a New Tool for Direct Mutation Detection from FFPE Tissue

Based on a literature review, the diagnostic sensitivity of the (under development) Idylla™ POLE Mutation Assay for detecting POLE mutations with evidence to support clinical utility, was 98% in endometrial cancer and 90% colorectal cancer. The new assay is currently undergoing evaluation at multiple selected sites across Europe and the US, using clinical endometrial carcinoma FFPE specimens. The conclusive results will be shared at the AMP conference⁵.

6. Same-Day Molecular Testing Results from Cytology Specimens: The Next Frontier of the Rapid On-site Evaluation?

This MDACC study demonstrated the feasibility of Idylla™ for rapid and accurate molecular testing of NSCLC and thyroid cancer biomarkers from cytology samples. Results were available in 2-3 hours, with high accuracy across KRAS, EGFR, BRAF and GeneFusion Assays, showing concordance rates of 94-100%⁶.

References

1. Ashutosh Vashisht, Ashis K Mondal, Lora Walczak, Vishakha Vashisht, Shubha Sharma, Pankaj Ahluwalia, Jana Woodall, Harmanpreet Singh, Ravindra Kolhe - Department of Pathology, Medical College of Georgia, Augusta University, GA, USA.

2. Katherine Drews-Elger, Rodrigo Santoscoy-Valencia, Catherine Garcia-Serje, Silvia Gonzalez-Leiva, Mayra Rodriguez, Orlando Bracho-Rincon, and Roberto Ruiz-Cordero - Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL - Jackson Memorial Hospital, Miami, FL - Clinical OncoMolecular Lab, Department of Pathology and Laboratory Medicine, University of Miami, Miami, FL.

3. Patricia Caffes, Gang Zheng M.D. Ph.D., Ying-Chun Lo M.D. Ph.D. - Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN - Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

4. Catalina Esguerra, Anthony Magliocco - Protean BioDiagnostics.

5. Sofie Metsu - Biocartis.

6. Dr. Gloria Sura - Cytology, MDACC.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>